Mycoplasma Testing Market

Mycoplasma Testing Market Size (2022 to 2027)

The size of the global mycoplasma testing market is estimated to worth USD 665.76 Million in 2022. This figure is forecasted to be growing at a CAGR of 12.7% to reach USD 1210.43 Million by 2027. 

Mycoplasma contamination of cell culture has been a growing concern for most researchers for decades. Mycoplasma infection mainly originates from laboratory workers, as contamination with human mycoplasmas occurs at a faster rate.

MARKET DRIVERS:

Mycoplasma testing is carried out to combat further contamination, which is expected to increase the demand for related products and, hence, the global mycoplasma testing market.

The demand for mycoplasma test products is expected to increase in the near future with growing investment in R & D in life sciences. Tremendous opportunities in the life sciences segment are driving the growth of the market. Increased investment in the biotechnology and pharmaceutical industries and increased healthcare spending is expected to further fuel growth.

The increased research activities of pharmaceutical and biotechnology companies are reflected in adopting new technologies for drug discovery and development. In 2019, Boehringer Ingelheim announced plans to invest approximately USD 261 million for its new Biological Development Center (BDC), which will be located at its R&D site in Germany. Merck also plans to invest $ 18 billion in R&D over the next five years, in addition to its annual investment of $ 7.2 billion. Therefore, it is expected that a significant amount of R&D expenditure will drive developments in this area, thereby stimulating the demand for mycoplasma testing products.

Government initiatives in the form of awareness campaigns on chronic diseases, such as cancer, also promote research-based activities that are expected to boost the global mycoplasma testing market.

The National Research Council's Industrial Research and Assistance Program (NRC-IRAP) provides technological support to small and medium-sized life science companies in Canada involved in product development and innovation. According to Saudi Arabia's Vision 2040, its government promotes the growth of pharmaceutical industries as only 35% of its drug needs are produced locally.

The increasing introduction of new technologies by key players is expected to further fuel the mycoplasma testing market growth.

Another factor that stimulates growth is increased contamination of cell cultures. Due to the limitation of culture methods, researchers are involved in identifying and developing faster and more accurate mycoplasma tests in recent years. These rapid tests' main advantages would be high sensitivity, the ability to identify a wide range of mycoplasma species, and reduced cycle time, thus reducing production time. Nucleic Acid-Based Technology (NAT), which allows rapid detection of mycoplasmas in cell culture, is an example of an alternative method for culture-based assays. In 2019, the American Type Culture Collection announced its new polymerase chain reaction (PCR) -based service that helps detect contaminants in mycoplasma cell cultures.

Multiple government authorities progressively support research activities in the pharmaceutical and biotechnology departments. For example, the U.S. government provides financial support to global pharmaceutical companies to facilitate research activities to develop new drugs. In April 2020, the United States Food and Drug Administration (FDA) announced plans to change the regulations for the only test method used to detect mycoplasmas. According to the agency, the regulations are restrictive and avoid using other testing methods that could potentially detect mycoplasmas accurately. These changes in biologics regulation are expected to improve mycoplasma testing's sensitivity and specificity by developing new technologies. Therefore, an increase in government funding for pharmaceutical and biotechnology research has stimulated R & D activities, promoting mycoplasma test products' wide application.

MARKET RESTRAINTS:

The success of mycoplasma testing depends primarily on the analysts' experience and the environmental conditions under which the test is performed. Mycoplasma testing should be performed for optimum effectiveness by trained professionals with sufficient knowledge of this area's nuances. The handling of instruments used in mycoplasma tests also requires experience. Hence, the shortage of sufficiently skilled human resources poses a significant challenge to the growth of the mycoplasma testing market.

Impact of COVID-19 on the global mycoplasma testing market:

The sudden eruption of coronavirus (COVID 19) caused by the SARS-CoV-2 reagent affected many industries, particularly healthcare. The pandemic crisis has induced the medical sector to find a remedy for the dangerous infectious disease. The pandemic is to have an unbiased impact on the mycoplasma testing market growth during 2020 and 2021. Some of the COVID 19 patients may respond to antibiotics and anti-malaria treatment positively. They could be the outcome of inhibition of Mycoplasma species and other bacterial infections in groups of patients. And may be helpful to use molecular tests to examine the appearance of mycoplasma species and other pathogenic bacteria that are frequently found in ordinary pneumonia among all the hospitalized COVID 19 patients. When obtained positive outcomes, patients need to be treated accordingly to develop responses clinically and patient results. 

REPORT COVERAGE:

This market research report on the global mycoplasma testing market has been segmented and sub-segmented into the following categories and analyzed market size and forecast until 2027.

Mycoplasma Testing Market – By Product:

• Kits & Reagent       
  • PCR Assays
  • Nucleic Acid Detection Kits
  • Elimination Kits & Reagents
  • Stains
  • Standards & Controls
  • Other Kits & Reagents
• Instruments           
• Services    

Based on the product type, the Kits & Reagents segment is likely to have the largest share during the period. 

Mycoplasma Testing Market – By Technique:

• PCR            
• ELSA           
• Direct Assays          
• Indirect Assays      
• Microbial culture techniques           
• Enzymatic Methods            
• DNA Staining          

Based on the Technique type, the Polymerase Chain Reaction (PCR) segment is expected to hold the highest share market and high CAGR value. It is attributed to the large receiving rate of PCR due to the exact, speedy, and ease of modification. This PCR technique is used extensively for detecting mycoplasma as this is very quick, cheap, and not influenced by cell culture conditions.

Mycoplasma Testing Market – By Application:

• Cell Line Testing    
• Virus Testing          
• Cell Testing     

Based on the Application type, the cell line testing segment is expected to have a high CAGR value during the period. The growth of this Application type is based on the factor like the growth rate of increasing pharmaceutical industries and clone that is derived from an individual antibody.

Mycoplasma Testing Market – By End User:

• Pharmaceutical Companies              
• Contract Research Organizations   
• Academic Research Institutes         
• Cell Banks

Based on the End-user, Pharmaceutical Companies share the highest market value attributed to the new innovative activities in the pharmaceutical and biotechnology companies.

Mycoplasma Testing Market – By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa

Geographically, North America dominates the global mycoplasma testing market, and Europe is not far behind.

In 2020, North America dominated the mycoplasma testing market due to increased healthcare spending and investment by the US government to promote biopharmaceutical industries' research activities. Biopharmaceutical production in North America is also growing, requiring highly purified cultures to produce therapeutic products. According to the National Science Foundation, in 2020, the R & D sector in the United States experienced significant growth, which is expected to influence regional development positively.

Asia-Pacific region is projected to have the fastest growth rate due to the enormous opportunities available in countries like China, India, and Japan. Asia-Pacific is anticipated to grow at a lucrative growth rate during the forecast period. It is due to the significant awareness and fundraising initiatives generated by countries like India. The Indian government is carrying out several strategic initiatives to facilitate additional R & D activities to introduce new drugs. Also, healthcare organizations' regulatory policies that promote improved quality of biosafety are expected to increase growth opportunities shortly. For example, China has several regulatory bodies, such as the Ministry of Health, which oversee the approval of experiments and laboratories and oversight of biosafety. Increasing pharma and biotech companies and their investments in R&D and various government initiatives are expected to drive market growth.

KEY MARKET PARTICIPANTS:

Some of the noteworthy companies dominating the global mycoplasma testing market profiled in the report are Thermo Fisher Scientific Inc., Minerva Biolabs GmbH, Charles River Laboratories International, Inc., Gibraltar Laboratories, Sartorius AG, Lonza Group Ltd., Merck KGaA, Roche Diagnostics, SGS S.A., American Type Culture Collection, InvivoGen, PromoCell GmbH, WuXi AppTec.

RECENT HAPPENINGS IN THE MARKET:

• On May 27, 2019, Roche Holding received FDA clearance for the Cobas 6800/8800 systems testing menu. This clearance is used for detecting the patients with symptoms or no symptoms of Trichomonas Vaginalis and Mycoplasma genitalium DNA.